Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial

PaperCitations, authors & open-access status

Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 106 citations, 2020 year and hybrid oa status.

106
Citations
2020
Year
hybrid
OA Status

Related on ScholarIQ

Miao Mo
Author
Journal of Clinical Oncology
Journal
Breast Cancer Treatment Studies
Topic
Breast Cancer Treatment Studies
Topic
Cancer Treatment and Pharmacology
Topic
Breast Lesions and Carcinomas
Topic
470M+ articles · free account